AMENDMENTS

CLAIM AMENDMENTS

31. *(Currently amended)* A method of stimulating an anti-tumor immune response or treating a neoplastic disease, comprising administering to a subject a composition comprising:

~~either a cell genetically altered to produce a cytokine at an elevated level, or the progeny of such a cell,~~

a cell expressing a cytokine from a recombinant polynucleotide,

wherein the cytokine is stably associated in the cell outer membrane ;

and wherein the cell has been inactivated to prevent proliferation.

32. *(Currently amended)* The method of claim 31, wherein the cytokine is selected from ~~the group consisting of~~ IL-4, GM-CSF, IL-2, TNF-α, and M-CSF.

33. *(Previously added)* The method of claim 31, wherein the cell is a cancer cell.

34. *(Currently amended)* The method of claim 31, wherein the cell is from a ~~cancer~~ tumor of the same tissue type as a tumor in the subject.

35. *(Currently amended)* The method of claim 34, wherein the ~~cancer~~ tumor is an ovarian cancer or a brain cancer.

36. *(Previously added)* The method of claim 31, wherein the cell is allogeneic to the subject.

37. *(Previously added)* The method of claim 31, wherein the cell is histocompatibly identical to the subject.

38. *(Previously added)* The method of claim 31, wherein the composition further comprises a tumor-associated antigen, and wherein the combination of the cytokine and the

tumor-associated antigen in the composition is effective in treating a neoplastic disease or eliciting an anti-tumor immunological response in the subject.

39. *(Previously added)* The method of claim 38, wherein the tumor-associated antigen is obtained from a cell autologous to the subject.

40. *(Previously added)* The method of claim 38, wherein the tumor-associated antigen is expressed by the same cells expressing the membrane-associated cytokine.

41. *(Previously added)* The method of claim 38, wherein the composition comprises a combination of:

a) the cell expressing the membrane-associated cytokine; and

b) a tumor cell autologous to the subject;

wherein the combination is effective in treating a neoplastic disease or eliciting an anti-tumor immunological response in the subject.

42. *(Previously added)* The method of claim 41, wherein the tumor cell is a primary tumor cell dispersed from a solid tumor obtained from the subject.

43. *(Previously added)* The method of claim 41, wherein the tumor cell is a glioma, a glioblastoma, a gliosarcoma, an astrocytoma, or an ovarian cancer cell.

44. *(Currently amended)* The method of claim 41, wherein the tumor cell ~~is inactivated~~ has been inactivated by irradiation.

B3

45. *(Currently amended)* The method of claim 31, wherein the cell expressing the membrane-associated cytokine ~~is inactivated~~ has been inactivated by irradiation.

46. *(Previously added)* The method of claim 31, wherein the cell produces a secreted cytokine in addition to the cytokine stably associated in the outer membrane.

47. *(Previously added)* The method of claim 31, wherein a majority of the cytokine produced by the cell is present on the outer membrane of the cell.

B4

48. *(Currently amended)* The method of claim 38, wherein the cytokine is selected from ~~the group consisting of~~ IL-4, GM-CSF, IL-2, TNF-α, and M-CSF.

49. *(Previously added)* The method of claim 31, wherein the composition comprises at least two cells, each of which has been genetically altered to produce a different cytokine at an elevated level, or is the progeny of such a cell, and wherein each cytokine is stably associated in the outer membrane of the cell.

B5

50. *(Currently amended)* A method of stimulating an anti-tumor immune response or treating a neoplastic disease, comprising administering to a subject a composition comprising a tumor associated antigen and a population of cells expressing a transmembrane cytokine, wherein the cells have been inactivated to prevent proliferation, and ~~at a level sufficient to stimulate~~ wherein the composition is effective in stimulating an immune response to the tumor associated antigen in the subject.

51. *(Previously added)* The method of claim 31, wherein the cell is a human cell.

52. *(Previously added)* The method of claim 31, wherein the cytokine naturally occurs as a membrane cytokine.

53. *(Previously added)* The method of claim 31, wherein the cytokine is a fusion protein comprising a heterologous transmembrane region.

54. *(Previously added)* The method of claim 31, wherein the cell has been transduced with a retroviral expression vector, or is the progeny of such a cell.

B6

55. *(Currently amended)* The method of claim 31, which is a method for ~~stimulating a primary~~ priming an anti-tumor immune response.

B6

56. *(Currenily amended)* The method of claim 31, which is a method for ~~stimulating a secondary~~ boosting or maintaining an anti-tumor immune response.

57. *(Previously added)* The method of claim 31, which is a method for treating a neoplastic disease.

58. *(Previously added)* The method of claim 31, further comprising providing the cytokine expressing cell that is present in the composition.

59. *(Previously added)* The method of claim 38, further comprising providing the tumor associated antigen that is present in the composition.

60. *(Previously added)* The method of claim 31, further comprising transducing a cancer cell with an expression vector encoding the membrane-associated cytokine.

61. *(New)* The method of claim 31, wherein the cytokine is IL-4.

62. *(New)* The method of claim 31, wherein the cytokine is GM-CSF.

63. *(New)* The method of claim 31, wherein the cytokine is M-CSF.

B7

64. *(New)* A method of stimulating an anti-tumor immune response or treating a neoplastic disease, comprising administering to a subject a composition containing an allogeneic cell genetically altered to produce a cytokine at an elevated level, or the progeny of such a cell, wherein the cytokine is stably associated in the cell outer membrane.

65. *(New)* The method of claim 64, wherein the cytokine is selected from IL-4, GM-CSF, IL-2, TNF-α, and M-CSF.

66. *(New)* The method of claim 64, wherein the cell is from a tumor of the same tissue type as a tumor in the subject.

67. *(New)* The method of claim 64, wherein the composition further comprises a tumor-associated antigen, and wherein the combination of the cytokine and the tumor-associated antigen in the composition is effective in treating a neoplastic disease or eliciting an anti-tumor immunological response in the subject.

68. *(New)* The method of claim 67, wherein the tumor-associated antigen is obtained from a cell autologous to the subject.

69. *(New)* The method of claim 67, wherein the tumor-associated antigen is expressed by the same cells expressing the membrane-associated cytokine.

70. *(New)* The method of claim 67, wherein the composition comprises a combination of:

a) the cell expressing the membrane-associated cytokine; and

b) a tumor cell autologous to the subject;

wherein the combination is effective in treating a neoplastic disease or eliciting an anti-tumor immunological response in the subject.

71. *(New)* The method of claim 70, wherein the tumor cell is a primary tumor cell dispersed from a solid tumor obtained from the subject.

72. *(New)* The method of claim 64, wherein the cell expressing the membrane-associated cytokine has been inactivated to prevent proliferation.

73. *(New)* The method of claim 64, wherein the cell expressing the membrane-associated cytokine has been irradiated.

74. *(New)* The method of claim 64, wherein the cell is a human cell.

75. *(New)* The method of claim 64, wherein the cytokine naturally occurs as a membrane cytokine.

B7

76. *(New)* The method of claim 64, wherein the cytokine is a fusion protein comprising a heterologous transmembrane region.

77. *(New)* The method of claim 64, which is a method for stimulating an immune response.

78. *(New)* The method of claim 64, which is a method for treating a neoplastic disease.